Hence, a highly specific ADRB-2 antagonist may be the ideal compound to treat VHL patients, as it would maintain the therapeutic properties of propranolol while avoiding its hypotension and bradycardia effects. Here, ADRB2 is linked to von Hippel-Lindau disease.